Literature DB >> 26090373

Advanced Anderson-Fabry disease presenting with left ventricular apical aneurysm and ventricular tachycardia.

Marie-France Poulin1, Alap Shah1, Richard G Trohman1, Christopher Madias1.   

Abstract

A 54-year-old female with Anderson-Fabry disease (AFD)-R342Q missense mutation on exon 7 in alpha-galactosidase A (GLA) gene - presented with sustained ventricular tachycardia. Imaging confirmed the presence of a new left ventricular apical aneurysm (LVAA) and a significantly reduced intra-cavitary gradient compared to two years prior. AFDcv is an X-linked lysosomal storage disorder caused by GLA enzyme deficiency. The phenotypic expression of AFD in the heart is not well described. Cardiac involvement can include left ventricular hypertrophy (LVH), which is typically symmetric, but can also mimic hypertrophic cardiomyopathy (HCM). Left ventricular apical aneurysm is a rare finding in HCM. We suggest a shared mechanism of LVAA formation in AFD and HCM, independent of the underlying cardiomyopathy. Mechanisms of LVAA formation in HCM include genetic predisposition and long-standing left ventricular wall stress from elevated intra-cavitary systolic pressures due to mid-cavitary obstruction. Both mechanisms are supported in this patient (a brother with AFD also developed a small LVAA). Screening for AFD should be considered in cases of unexplained LVH, particularly in patients with the aneurysmal variant of HCM.

Entities:  

Keywords:  Anderson-Fabry disease; Hemodynamic compensation; Hypertrophic cardiomyopathy; Left ventricular apical aneurysm; Magnetic resonance imaging; Sustained ventricular tachycardia; Transthoracic echocardiography

Year:  2015        PMID: 26090373      PMCID: PMC4468899          DOI: 10.12998/wjcc.v3.i6.519

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  11 in total

Review 1.  Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy.

Authors:  Robert Roberts; Ulrich Sigwart
Journal:  Circulation       Date:  2005-07-12       Impact factor: 29.690

Review 2.  The heart in Anderson-Fabry disease and other lysosomal storage disorders.

Authors:  Ales Linhart; Perry M Elliott
Journal:  Heart       Date:  2007-04       Impact factor: 5.994

3.  Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; John J Finley; J Martijn Bos; Thomas H Hauser; Warren J Manning; Tammy S Haas; John R Lesser; James E Udelson; Michael J Ackerman; Barry J Maron
Journal:  Circulation       Date:  2008-09-22       Impact factor: 29.690

4.  Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin.

Authors:  D J Callans; V Menz; D Schwartzman; C D Gottlieb; F E Marchlinski
Journal:  J Am Coll Cardiol       Date:  1997-04       Impact factor: 24.094

5.  Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography.

Authors:  Masaru Ichida; Yoshioki Nishimura; Kazuomi Kario
Journal:  J Cardiol       Date:  2014-03-25       Impact factor: 3.159

6.  Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes.

Authors:  Dominique P Germain; Junaid Shabbeer; Sylvie Cotigny; Robert J Desnick
Journal:  Mol Med       Date:  2002-06       Impact factor: 6.354

7.  Continuous apex to left ventricle blood flow pattern in hypertrophic cardiomyopathy with apical aneurysm and midventricular obstruction.

Authors:  Bill P C Hsieh; James Tauras; Cynthia Taub
Journal:  Echocardiography       Date:  2012-02-13       Impact factor: 1.724

8.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

9.  A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.

Authors:  Xiaoyang Wu; Evan Katz; Maria Cecilia Della Valle; Kirsten Mascioli; John J Flanagan; Jeffrey P Castelli; Raphael Schiffmann; Pol Boudes; David J Lockhart; Kenneth J Valenzano; Elfrida R Benjamin
Journal:  Hum Mutat       Date:  2011-07-12       Impact factor: 4.878

10.  Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.

Authors:  Cristina Chimenti; Maurizio Pieroni; Emanuela Morgante; Daniela Antuzzi; Andrea Russo; Matteo Antonio Russo; Attilio Maseri; Andrea Frustaci
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

View more
  1 in total

Review 1.  Anderson-Fabry disease in heart failure.

Authors:  M M Akhtar; P M Elliott
Journal:  Biophys Rev       Date:  2018-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.